ReviewBMJ neurology open2026
Advances in cerebrovascular reserve function assessment for moyamoya disease.
Review in BMJ neurology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moyamoya disease (MMD) is a rare cerebrovascular disease characterised by gradual progressive stenosis and occlusion of the terminal internal carotid arteries, anterior cerebral arteries and proximal middle cerebral arteries bilaterally. This pathology leads to the formation of a compensatory and fragile collateral vascular network at the brain's base. With disease progression, MMD may result in ischaemic or haemorrhagic stroke. However, the lack of reliable and effective methods to assess disease progression leaves many patients at high risk of stroke without timely clinical intervention. Therefore, determining the disease course and assessing stroke risk are critical. Cerebrovascular reserve (CVR) reflects the ability of brain tissue to increase blood flow under stress. CVR evaluation assists clinicians in understanding MMD severity, guiding therapeutic decisions and determining prognosis. This narrative review analyses recent literature, highlights the advantages and disadvantages of various CVR assessment techniques, and discusses the interplay between CVR and MMD. In addition, it examines the role of CVR in evaluating disease progression and associated treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.